•    Active primary Subfoveal Choroidal Neovascularization lesions secondary to Age-related macular degeneration (AMD) in the study eye

•    Best corrected visual acuity of 35-75 letters read (20/32 to 20/200 Snellen equivalent)

•    Study eye must:

•    Have active leakage on Fluorescein Angiogram involving the fovea

•    Have edema involving the fovea

•    Be free of scarring, fibrosis, or atrophy involving the central foveal zone

•    Previous subfoveal focal laser photocoagulation in the study eye

•    Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1-month preceding randomization

•    Any concurrent intraocular condition in the study eye that may require medical or surgical intervention or contribute to vision loss within 1 year

•    Active intraocular inflammation (grade trace or above) in the study eye

•    Current vitreous hemorrhage in the study eye

•    Polypoidal choroidal vasculopathy (PCV) in the study eye

•    History of idiopathic or autoimmune-associated uveitis in either eye

•    Infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye

•    Uncontrolled glaucoma in the study eye (defined as intraocular pressure =30 mmHg despite treatment with anti-glaucoma medication)

•    Premenopausal women not using adequate contraception

•    Current treatment for active systemic infection

•    Known allergy to any component of the study drug or history of allergy to fluorescein , not amenable to treatment

• Ophthalmology

• Preventative Medicine

• Outlook Therapeutics, Inc.